TEL AVIV, Israel, Nov. 18, 2016 /PRNewswire/ -- Tikcro Technologies Ltd. (OTCQX: TIKRF) today reported results for the third quarter ended September 30, 2016.
Aviv Boim, CEO of Tikcro, commented, “We are continuing our pre-clinical research efforts to identify new immune-modulation antibodies for cancer treatment. By leveraging a unique immunization approach for the generation of antibodies, we aim to develop antibodies with blocking qualities to a handful of immune modulator domains. We are conducting animal immunization with proprietary antigens, followed by high throughput screening of derived B-cells. We are pursuing this process with several targets and antigens and intend to continue to conduct rounds of these studies with an aim to identify leading antibodies to a handful of targeted domains.”
